Tuberculosis biomarkers discovery: developments, needs, and challenges

Detalhes bibliográficos
Autor(a) principal: Wallis, Robert S
Data de Publicação: 2013
Outros Autores: Kim, Peter, Cole, Stewart, Hanna, Debra, Andrade, Bruno de Bezerril, Maeurer, Markus, Schito, Marco, Zumla, Alimuddin
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/25829
Resumo: Andrade, Bruno Bezerril. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.
id CRUZ_ebdf8b47811e0a150e92221bcbece144
oai_identifier_str oai:www.arca.fiocruz.br:icict/25829
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Wallis, Robert SKim, PeterCole, StewartHanna, DebraAndrade, Bruno de BezerrilMaeurer, MarkusSchito, MarcoZumla, Alimuddin2018-04-12T17:29:06Z2018-04-12T17:29:06Z2013WALLIS, R. S. et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infectious Diseases, v. 13, p. 362–372, 2013.1473-3099https://www.arca.fiocruz.br/handle/icict/25829Andrade, Bruno Bezerril. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.European and Developing Countries Clinical Trials Partnership (EDCTP), Netherlands, EDCTP grants REMOX PANACEA (AZ), and TB-NEAT (MM, AZ); UK Medical Research Council (AZ); UBS Optimus Foundation, Switzerland (AZ, MM); University College London Hospitals (UCLH) Comprehensive Biomedical Research Centre (AZ); NIH Intramural Research Program (BBA); and the UCLH National Health Service Foundation Trust (AZ).Western Reserve University. Specialty Care. Pfizer, Groton. Departments of Medicine, Case. Cleveland, OH, USA / University of Medicine and Dentistry of New Jersey. Newark, NJ, USANational Institutes of Health, National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Division of AIDS and Immunobiology Section. Bethesda, MD, USAGlobal Health Institute. Ecole Polytechnique Fédérale de Lausanne. Lausanne, SwitzerlandCritical Path Institute. Salt Lake City. UT, USANational Institutes of Health, National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Division of AIDS and Immunobiology Section. Bethesda, MD, USAKarolinska Institute and CAST. Karolinska Hospital. LabMed and MTC. Division of Therapeutic Immunology. Stockholm, SwedenNational Institutes of Health. National Institute of Allergy and Infectious Diseases. Henry M Jackson Foundation-Division of AIDS. Bethesda, MD, USAUniversity College London. Centre for Clinical Microbiology. Division of Infection and Immunity. London, UK / University of Zambia. University College London Medical School. University Teaching Hospital. Research and Training Programme. Lusaka, ZambiaBiomarkers are indispensable to the development of new tuberculosis therapeutics and vaccines. The most robust biomarkers measure factors that are essential to the underlying pathological process of the disease being treated, and thus can capture the full eff ects of many types of interventions on clinical outcomes in multiple prospective, randomised clinical trials. Many Mycobacterium tuberculosis and human biomarkers have been studied over the past decade. Present research focuses on three areas: biomarkers predicting treatment effi cacy and cure of active tuberculosis, the reactivation of latent tuberculosis infection, and the induction of protective immune responses by vaccination. Many older, non-specifi c markers of infl ammation, when considered in isolation, do not have suffi cient predictive values for clinical use in tuberculosis. Although no new accurate, tuberculosis-specifi c biomarkers have yet been discovered, substantial progress has been made in some areas. However, the qualifi cation of biomarkers as a surrogate for a clinical endpoint in tuberculosis is very challenging, and, for biomarkers that are non-culture-based, impossible to pursue without the availability of well characterised biobanks containing biospecimens from patients who have had adequate follow-up to establish long-term treatment outcome. We review progress in tuberculosis biomarker development and eff orts being made to harness resources to meet future challenges.engElsevierTuberculoseBiomarcadoresVacinasMycobacterium tuberculosisTratamentoHumanosTuberculosisBiomarkersVaccinesMycobacterium tuberculosisTreatmentHumansTuberculosis biomarkers discovery: developments, needs, and challengesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/25829/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALWallis RS Tuberculosis biomarkers discovery....pdfWallis RS Tuberculosis biomarkers discovery....pdfapplication/pdf395497https://www.arca.fiocruz.br/bitstream/icict/25829/2/Wallis%20RS%20Tuberculosis%20biomarkers%20discovery....pdfa3ac657946c25a2aac845de5db730444MD52TEXTWallis RS Tuberculosis biomarkers discovery....pdf.txtWallis RS Tuberculosis biomarkers discovery....pdf.txtExtracted texttext/plain70625https://www.arca.fiocruz.br/bitstream/icict/25829/3/Wallis%20RS%20Tuberculosis%20biomarkers%20discovery....pdf.txtb83fe0c3bc8d4a7d1fea8ea9b41242d7MD53icict/258292023-03-15 14:34:07.776oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:07Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Tuberculosis biomarkers discovery: developments, needs, and challenges
title Tuberculosis biomarkers discovery: developments, needs, and challenges
spellingShingle Tuberculosis biomarkers discovery: developments, needs, and challenges
Wallis, Robert S
Tuberculose
Biomarcadores
Vacinas
Mycobacterium tuberculosis
Tratamento
Humanos
Tuberculosis
Biomarkers
Vaccines
Mycobacterium tuberculosis
Treatment
Humans
title_short Tuberculosis biomarkers discovery: developments, needs, and challenges
title_full Tuberculosis biomarkers discovery: developments, needs, and challenges
title_fullStr Tuberculosis biomarkers discovery: developments, needs, and challenges
title_full_unstemmed Tuberculosis biomarkers discovery: developments, needs, and challenges
title_sort Tuberculosis biomarkers discovery: developments, needs, and challenges
author Wallis, Robert S
author_facet Wallis, Robert S
Kim, Peter
Cole, Stewart
Hanna, Debra
Andrade, Bruno de Bezerril
Maeurer, Markus
Schito, Marco
Zumla, Alimuddin
author_role author
author2 Kim, Peter
Cole, Stewart
Hanna, Debra
Andrade, Bruno de Bezerril
Maeurer, Markus
Schito, Marco
Zumla, Alimuddin
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Wallis, Robert S
Kim, Peter
Cole, Stewart
Hanna, Debra
Andrade, Bruno de Bezerril
Maeurer, Markus
Schito, Marco
Zumla, Alimuddin
dc.subject.other.pt_BR.fl_str_mv Tuberculose
Biomarcadores
Vacinas
Mycobacterium tuberculosis
Tratamento
Humanos
topic Tuberculose
Biomarcadores
Vacinas
Mycobacterium tuberculosis
Tratamento
Humanos
Tuberculosis
Biomarkers
Vaccines
Mycobacterium tuberculosis
Treatment
Humans
dc.subject.en.pt_BR.fl_str_mv Tuberculosis
Biomarkers
Vaccines
Mycobacterium tuberculosis
Treatment
Humans
description Andrade, Bruno Bezerril. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.
publishDate 2013
dc.date.issued.fl_str_mv 2013
dc.date.accessioned.fl_str_mv 2018-04-12T17:29:06Z
dc.date.available.fl_str_mv 2018-04-12T17:29:06Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv WALLIS, R. S. et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infectious Diseases, v. 13, p. 362–372, 2013.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/25829
dc.identifier.issn.pt_BR.fl_str_mv 1473-3099
identifier_str_mv WALLIS, R. S. et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infectious Diseases, v. 13, p. 362–372, 2013.
1473-3099
url https://www.arca.fiocruz.br/handle/icict/25829
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/25829/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/25829/2/Wallis%20RS%20Tuberculosis%20biomarkers%20discovery....pdf
https://www.arca.fiocruz.br/bitstream/icict/25829/3/Wallis%20RS%20Tuberculosis%20biomarkers%20discovery....pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
a3ac657946c25a2aac845de5db730444
b83fe0c3bc8d4a7d1fea8ea9b41242d7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324754664390656

Registros relacionados